Morphogenesis, Inc.

Founded in 1995, the prime focus of Morphogenesis, Inc., a Florida Biotechnology Corporation, has resulted in the development of a multi-indication personalized therapeutic cancer vaccine, ImmuneFx™,which primes and educates the immune system to attack tumor cells throughout the body without damaging other cells or systems, and without side effects. Manufacturing processes are rapid, efficient and cost effective.